{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:23:50Z","timestamp":1786998230907,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xkme.2024.100896","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T21:45:55Z","timestamp":1724795155000},"page":"100896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Allopurinol, Febuxostat, and Nonuse of Xanthine Oxidoreductase Inhibitor Treatment in Patients Receiving Hemodialysis: A Longitudinal Analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Takeo","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodoka","family":"Seya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashio","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2024.100896_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106407","article-title":"Chronic kidney disease: which role for xanthine oxidoreductase activity and products?","volume":"184","author":"Polito","year":"2022","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.xkme.2024.100896_bib2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","article-title":"Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk","volume":"79","author":"Borghi","year":"2022","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.xkme.2024.100896_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/2211-5463.13083","article-title":"Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy","volume":"11","author":"Ishii","year":"2021","journal-title":"FEBS Open Bio"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13970-4","article-title":"Evaluation of the effectiveness of xanthine oxidoreductase inhibitors on haemodialysis patients using a marginal structural model","volume":"7","author":"Ishii","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xkme.2024.100896_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xkme.2024.100896_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.xkme.2024.100896_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2022.08.001","article-title":"Intestinal hyperuricemia as a driving mechanism for CKD","volume":"81","author":"Johnson","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2024.100896_bib8","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/srep03755","article-title":"ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload","volume":"4","author":"Matsuo","year":"2014","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xkme.2024.100896_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2022.05.010","article-title":"Urate transporter ABCG2 function and asymptomatic hyperuricemia: a retrospective cohort study of CKD progression","volume":"81","author":"Ohashi","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"10.1016\/j.xkme.2024.100896_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10264","key":"10.1016\/j.xkme.2024.100896_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.xkme.2024.100896_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00296-022-05139-8","article-title":"Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017","volume":"42","author":"Weisshaar","year":"2022","journal-title":"Rheumatol Int"},{"issue":"454","key":"10.1016\/j.xkme.2024.100896_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1198\/016214501753168154","article-title":"Marginal structural models to estimate the joint causal effect of nonrandomized treatments","volume":"96","author":"Hern\u00e1n","year":"2001","journal-title":"JASA"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12874-017-0434-1","article-title":"Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination","volume":"17","author":"Lusivika-Nzinga","year":"2017","journal-title":"BMC Med Res\u00a0Methodol"},{"issue":"4","key":"10.1016\/j.xkme.2024.100896_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/EDE.0b013e31824d1ccb","article-title":"Estimating the effects of multiple time-varying exposures using joint marginal structural models: alcohol consumption, injection drug use, and HIV acquisition","volume":"23","author":"Howe","year":"2012","journal-title":"Epidemiol"},{"issue":"5","key":"10.1016\/j.xkme.2024.100896_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiol"},{"issue":"5","key":"10.1016\/j.xkme.2024.100896_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiol"},{"key":"10.1016\/j.xkme.2024.100896_bib19","unstructured":"International Statistical Classification of Diseases and Related Health Problems 10th Revision-10. 5th ed. https:\/\/icd.who.int\/browse10\/2019\/en."},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jvs.2019.09.040","article-title":"Translating coding lists in administrative claims-based research for cardiovascular procedures","volume":"72","author":"Wanken","year":"2020","journal-title":"J\u00a0Vasc Surg"},{"issue":"4","key":"10.1016\/j.xkme.2024.100896_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/aje\/kwaa225","article-title":"Common methods for handling missing data in marginal structural models: what works and why","volume":"190","author":"Leyrat","year":"2021","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.xkme.2024.100896_bib22","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"issue":"3","key":"10.1016\/j.xkme.2024.100896_bib23","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.xkme.2024.100896_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","article-title":"The proportion of missing data should not be used to guide decisions on multiple imputation","volume":"110","author":"Madley-Dowd","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.xkme.2024.100896_bib25","series-title":"Generalized Additive Models","author":"Hastie","year":"1990"},{"issue":"6","key":"10.1016\/j.xkme.2024.100896_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100896_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/aje\/kwp418","article-title":"Time scale and adjusted survival curves for marginal structural cox models","volume":"171","author":"Westreich","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"10.1016\/j.xkme.2024.100896_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s Regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Statist"},{"issue":"2","key":"10.1016\/j.xkme.2024.100896_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"issue":"12","key":"10.1016\/j.xkme.2024.100896_bib31","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2215\/CJN.12841216","article-title":"Statistical methods for recurrent event analysis in cohort studies of CKD","volume":"12","author":"Yang","year":"2017","journal-title":"Clin J Am Soc\u00a0Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/0886022X.2020.1835674","article-title":"Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients","volume":"42","author":"Rohn","year":"2020","journal-title":"Ren Fail"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53965-x","article-title":"Febuxostat, a xanthine oxidoreductase inhibitor, decreases NLRP3-dependent inflammation in macrophages by activating the purine salvage pathway and restoring cellular bioenergetics","volume":"9","author":"Nomura","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.xkme.2024.100896_bib34","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bbadis.2014.05.022","article-title":"Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme","volume":"1842","author":"Battelli","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xkme.2024.100896_bib35","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","article-title":"Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice","volume":"4","author":"Nomura","year":"2014","journal-title":"Sci Rep"},{"issue":"4-6","key":"10.1016\/j.xkme.2024.100896_bib36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/15257770.2013.865743","article-title":"Hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiencies: HPRT1 mutations in new Japanese families and PRPP concentration","volume":"33","author":"Yamada","year":"2014","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"11","key":"10.1016\/j.xkme.2024.100896_bib37","doi-asserted-by":"crossref","first-page":"F1366","DOI":"10.1152\/ajprenal.00517.2015","article-title":"Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury","volume":"310","author":"Kamijo-Ikemori","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tips.2005.11.007","article-title":"The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins","volume":"27","author":"van Herwaarden","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.xkme.2024.100896_bib39","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-04-0078","article-title":"Phytoestrogens\/flavonoids reverse breast cancer resistance protein\/ABCG2-mediated multidrug resistance","volume":"64","author":"Imai","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.xkme.2024.100896_bib40","first-page":"611","article-title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance","volume":"1","author":"Imai","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1523-1755.2004.00354.x","article-title":"Characterization of uremic toxin transport by organic anion transporters in the kidney","volume":"65","author":"Deguchi","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib42","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1038\/s41598-021-86662-9","article-title":"Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1\/3 and ABCG2","volume":"11","author":"Taniguchi","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xkme.2024.100896_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41598-022-26519-x","article-title":"Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients","volume":"13","author":"Ohashi","year":"2023","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2024.100896_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10157-019-01836-0","article-title":"Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects","volume":"24","author":"Nakatani","year":"2020","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2024.100896_bib45","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1124\/mol.105.011080","article-title":"Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP\/ABCG2) in liver","volume":"67","author":"Merino","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100896_bib46","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"3-4","key":"10.1016\/j.xkme.2024.100896_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000530972","article-title":"Comparison between the effects of allopurinol and febuxostat on the survival of patients on maintenance hemodialysis","volume":"54","author":"Kang","year":"2023","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2024.100896_bib48","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2018050514","article-title":"Cardiovascular events after new-onset atrial fibrillation in adults with CKD: results from the\u00a0Chronic Renal Insufficiency Cohort (CRIC) study","volume":"29","author":"Bansal","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T05:33:54Z","timestamp":1731735234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059524001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2590059524001079"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100896","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allopurinol, Febuxostat, and Nonuse of Xanthine Oxidoreductase Inhibitor Treatment in Patients Receiving Hemodialysis: A Longitudinal Analysis","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100896"}}